/C O R R E C T I O N — Innovent Biologics/

/C O R R E C T I O N -- Innovent Biologics/

PR Newswire

SAN FRANCISCO and SUZHOU, China, May 21, 2026

In the news release, 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety, issued 21-May-2026 by Innovent Biologics over PR Newswire, we are advised by the company that the [In the Keynote‑407 study, in first‑line squamous NSCLC patients treated with PD‑1 combined with chemotherapy, the ORRs were 67.4% and 54.5% for the PD‑L1 1–49% and PD‑L1 <1% subgroups, respectively.] sentence, should read "[the ORRs were 54.5% and 67.4% for the PD‑L1 1–49% and PD‑L1 <1% subgroups]" rather than "[the ORRs were 67.4% and 54.5% for the PD‑L1 1–49% and PD‑L1 <1% subgroups]" as originally issued inadvertently. The complete, corrected release follows:

2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety